



SDI Review Form 1.6

Journal Name:	International Journal of Medical and Pharmaceutical Case Reports
Manuscript Number:	Ms_IJMPCR_36791
Title of the Manuscript:	Atypical Femoral Fractures Following Use of Reclast™ After Prior Treatment with Alendronate: A Clinical Practice Series and Opinion
Type of the Article	Clinical Practice Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	<ul style="list-style-type: none"> - Maybe the title is confusing. When you read the title of the paper you think in a case series with people who has been taken only Alendronate and after Zoledronic infusion has had a fracture. When you read the paper there is a mix of treatments and Zoledronic infusion is one of the treatments (one of the patient has taken Prolia after Zoledronic infusion). My recommendation is to revise the title. - In Introduction you talk about the experiences in your group. Maybe you have to include these experiences in discussion where you talk about this and give another point of view to the introduction. - Talk about Zoledronic as a responsible of all the cases after administration of the drug is adventured. As you say in discussion the effect of BPs maintains more that 10 years in bone. Maybe it would be more adecuate talk about the summatory effects of BPs and include the paragraph you talk about the potency and the effects of different BPs in the introduction. - In the title, please use the generic name of the drug. In some countries Zoledronic is commercialized as a gneric drug or has a different name. This is extensible to all the text. 	
Minor REVISION comments	It could be fantastic if you colud add some images of the fractures.	
Optional/General comments	The paper is very interesting and the authors have experience in the management of these patients. I think that the paper should be accepted, but structural changes have to been made to make the text more comprehensible to readers not experts in the field. In my opinion these changes in structure will improve the quality of the paper significantly.	

Reviewer Details:

Name:	Rafael Sanjuan-Cervero
Department, University & Country	Ortgopedics and Traumatology department. Hospital de Denia, Alicante, Spain